Cargando…

Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Bank, Thomas, Malnassy, Gregory, Arteaga, Maribel, Shang, Na, Dalheim, Annika, Ding, Xianzhong, Cotler, Scott J., Denning, Mitchell F., Nishimura, Michael I., Breslin, Peter, Qiu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983153/ https://www.ncbi.nlm.nih.gov/pubmed/29881824 http://dx.doi.org/10.1002/hep4.1181

Ejemplares similares

Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation
por: Shang, Na, et al.
Publicado: (2018)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression
por: Malnassy, Greg, et al.
Publicado: (2023)

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
por: Gu, Ha Ra, et al.
Publicado: (2015)

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma
por: Zheng, Min, et al.
Publicado: (2017)

Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth
por: Li, Hao, et al.
Publicado: (2019)

Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells
por: Yang, Qu, et al.
Publicado: (2021)

Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling
por: Maruwge, Wessen, et al.
Publicado: (2008)

MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor
por: Xiao, Yao, et al.
Publicado: (2016)

Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma
por: YOKOTA, Shohei, et al.
Publicado: (2022)

FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy
por: Shang, Na, et al.
Publicado: (2016)

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines
por: Riedel, Matthias, et al.
Publicado: (2016)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma
por: Wang, Fang, et al.
Publicado: (2021)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

α‐Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis
por: Wang, Qiujiao, et al.
Publicado: (2022)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy
por: Zhao, Fangfang, et al.
Publicado: (2021)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2
por: Wang, Guanghui, et al.
Publicado: (2019)

Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
por: Ou, Da-Liang, et al.
Publicado: (2013)

Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells
por: Zhang, Yunjie, et al.
Publicado: (2018)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression
por: Bie, Cai Qun, et al.
Publicado: (2016)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance
por: Zhao, Wei, et al.
Publicado: (2021)

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
por: Kusakabe, Yuko, et al.
Publicado: (2021)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
por: Davidi, Shiri, et al.
Publicado: (2022)

Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
por: Peng, Syue-Wei, et al.
Publicado: (2023)

Fucoidan Inhibits the Growth of Hepatocellular Carcinoma Independent of Angiogenesis
por: Zhu, Cong, et al.
Publicado: (2013)

Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis
por: Jennemann, Richard, et al.
Publicado: (2017)

Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
por: Ding, Wenbo, et al.
Publicado: (2022)

Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors
por: Fendrich, Volker, et al.
Publicado: (2012)

Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways
por: Fan, Lixia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_misdp1kl52lnm9cjj60qkc1571